Amplia Therapeutics Ltd Company Profile

Tackling significant unmet needs in cancer and fibrosis

Amplia Therapeutics Limited is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

  • Company
    Amplia Therapeutics Ltd
  • Website
  • Sector
  • Industry
  • Code
  • Socials

Company Overview

Star icon Promoted

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Share this profile:

The Right Assets, The Right People And The Right Investors At The Right Time.

Amplia's technology is addressing a multi-billion-dollar market by targeting fibrotic cancer & chronic fibrotic diseases.
Unmet Need

Checkpoint inhibitors have revolutionised cancer treatment, however complete response rates are still low. FAK inhibitors could improve the efficacy of immunotherapies.


Institutional investor Platinum International Health Care Fund, one of Australia’s leading biotechnology investors, are new cornerstone investors in Amplia.


The Amplia team have significant experience commercialising drugs, and recent SAB appointment Professor Paul Timpson is considered a world leader in FAK biology.

ASX presentation

Click here to view the latest presentation

The right opportunity...

Amplia are among the first in the world to explore how FAK could expand the growing multi-billion-dollar checkpoint inhibitor market. The global immune checkpoint inhibitors market was valued at $10,566 million in 2017, and is projected to reach $56,530 million by 2025, registering a CAGR of 20.1% from 2018 to 2025. (Source: Allied Market Research). Historical growth in this market has also been significant (see image).

...being tackled by the right assets...

Amplia's AMP886 and AMP945 are targeting several conditions within both Cancer and Fibrosis, which gives them an opportunity to take 'multiple shots at goal'. Furthermore, early studies have demonstrated that Amplia's molecules are highly differentiated and competitive. AMP945 in particular is believed to be highly focused in what it targets, which could suggest improved safety characteristics in comparison to other FAK assets currently being developed.

...being managed by the right people...

The Amplia board have a significant track record in the development and commercialisation of drugs. A comprehensive list of achievements can be found here, and includes but is not limited to multi-billion-dollar transactions to big-pharma in the U.S. In addition, Amplia's Scientific Advisory Board consists of world leaders in FAK biology, including recent appointment Professor Paul Timpson.
Profile image
Warwick Tong MB ChB MPP GAICD
Non-Executive Chairman
Profile image
John Lambert PhD GAICD
Chief Executive Officer & Managing Director
Profile image
Robert Peach PhD
Independent Non-Executive Director
Profile image
Christopher Burns BSc (Hons) PhD GAICD
Non-Executive Director

....and supported by the right investors...

Taylor Collison acted as the lead manager of Amplia's recent capital raising. Platinum International Health Care Fund, which has a portfolio size of ~A$300m, participated in this placement and became a cornerstone investor in Amplia.

... at the right time.

There is strong international interest in Amplia's target market, with NASDAQ listed company Verastem (NASDAQ:VSTM) raising ~US$100m (at a 12.6% premium to its closing price) from institutional investors to advance its FAK inhibitor combination therapy. Furthermore, Amplia's ASX-listed peers (that are developing drugs in cancer or fibrosis) have significantly higher market capitalisations. Amplia are expecting to commence Phase 1 trials as early as Q3 CY2020.
Clock icon Information current at 02 June 2020
This section contains information provided by Amplia Therapeutics Ltd, with the exception of any sections labeled as "risks". Although all due care has been taken, Mawson Graham ("SmallCapInsider") does not warrant the accuracy of the information provided in this section. It is not intended as an offer, invitation solicitation or recommendation with respect to the purchase or sale of any securities. The above information should not be relied upon as the sole representation of any matter that a potential investor should consider in evaluating Amplia Therapeutics Ltd. Its affiliates or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to or endorsement of, the accuracy or completeness of any information, statements, representations or forecasts contained above, and they do not accept any liability for any statement made in, or omitted from, the above. Prospective investors should make their own independent evaluation of an investment in Amplia Therapeutics Ltd. This information may contain forward looking statements concerning Amplia Therapeutics Ltd. Forward-looking statements are not statements of historical fact and actual events and results may differ materially from those described in the forward looking statements as a result of a variety of risks, uncertainties and other factors. Forward-looking statements are inherently subject to business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in any forward-looking information provided by Amplia Therapeutics Ltd, or on behalf of Amplia Therapeutics Ltd. Forward looking statements are based on Amplia Therapeutics Ltd's beliefs, opinions and estimates. No obligation is assumed to update forward looking statements if these beliefs, opinions and estimates should change or to reflect other future developments.

News Coverage

Current news mentioning Amplia Therapeutics Ltd from top publishers around the web.
Powered by  

Key Announcements

Management comments and explanations on key company announcements.
Need a full list of every announcement? Visit ASX

How do I invest?

Considering investing in Amplia Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:ATX

    On your online investment platform search for the stock ticker code ASX:ATX to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.